Along with these studies and several additional meta-analyses, it can be concluded that GLP-1R agonists, especially liraglutide and semaglutide, are successful in inducing substantial weight reduction, are well tolerated, and also show signs of improving obesity-related risk factors [80,81]. The gene discussed is GLP1R; the disease is Obesity.